Health economics provides a framework for evaluating the allocation of limited resources in healthcare, ensuring that interventions not only deliver clinical benefit but also represent optimal use of ...
Rob Abbott, CEO, ISPOR, explains how health economics and outcomes research is helping healthcare systems measure the true value of treatments, improve patient outcomes, and address rising drug costs ...
Multicancer early detection testing results in extended life-years and reduced cancer treatment costs through earlier diagnosis, leading to a cost-effective option in cancer screening. Objectives: ...
CAR-T therapy's cost per QALY is approximately $100,000, with consistent results across PSM, STM, and DES models. DES uniquely incorporates wait time, significantly affecting CAR-T's ...
This blog post is more than 6 months old. While it reflects the information available at the time, some details may now be out-of-date. Cost-effectiveness thresholds play a vital role in healthcare ...
A new analysis from the Institute for Clinical and Economic Review has found that blockbuster GLP-1 drugs from Novo Nordisk and Eli Lilly offer substantial health benefits and are a cost-effective ...
VEN+O is a cost-effective treatment for untreated, fit CLL patients, offering superior progression-free survival and cost savings compared to most alternatives. The study used a cost-utility analysis, ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S. drug cost watchdog has provided a final analysis that includes a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback